Stockwatch

Sirona Biochem Corp
Symbol	SBM
Shares Issued	253,604,505
Close 2023-11-28	C$ 0.085
Market Cap	C$ 21,556,383
Recent Sedar+ Documents

Sirona finds four compounds show anti-viral activity

2023-11-29 16:14 ET - News Release

Subject: Sirona Biochem Release-ICGEB Research Results Nov 2023 PDF Document File: Attachment SBM ICGEB Research Results #2 Nov 2023.pdf Sirona Biochem Receives Antiviral Testing Results Vancouver, Canada Nov 29, 2023 Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") announces the results of its research collaboration with the International Centre for Genetic Engineering and Biotechnology ("ICGEB") in advancing Sirona's antiviral compound library. The ICGEB has completed a successful screening of a second compound library from Sirona's subsidiary TFChem, evaluating its potential as inhibitors of SARS-CoV2. The library, comprised of 18 novel compounds, underwent testing at the ICGEB's Laboratory of Molecular Virology in Trieste, Italy. The testing was led by Dr. Alessandro Marcello, an internationally recognized expert in Human Virology. Among the 18 compounds, four exhibited notable antiviral activity. The results of the testing and the selective index, which gauges potency versus toxicity, does not currently identify a lead compound. Consequently, the 38 compounds synthesized so far are not considered candidates for developing a treatment for SARS-CoV2 in humans. Sirona will be reviewing its collaboration agreement with the ICGEB after further discussions. Potential options include testing the compounds against other pathogenic viruses and also analyzing their effect on living cells to confirm their targeted mechanism of action. Standardized testing procedures are available for these assessments. "Although these results may not endorse a potential treatment for SARS-CoV2, Dr. Howard Verrico, CEO, emphasizes the significance of further testing to assess the potential in the broader battle against other pathogenic viruses. The absence of potent antivirals for numerous classes of pathogenic viruses underscores the significance of this project as a worthwhile endeavor. He notes, 'The timing of additional testing will be determined through further assessment and expert consultations. ' Sirona is currently driving forward with compelling developments in its pipeline, giving precedence to initiatives aimed at sparking near-term revenue growth. Expect updates on these initiatives, which will be shared as soon as they progress to more advanced stages of planning. The company maintains an optimistic outlook, fueled by enthusiasm for the promising prospects that lie ahead in its ongoing ventures." About the International Centre for Genetic Engineering and Biotechnology Established in 1983 as a special project of UNIDO, the International Centre for Genetic Engineering and Biotechnology - ICGEB is an independent intergovernmental organization with HQ in Trieste (Italy) and with additional laboratories in New Delhi (India) and Cape Town (South Africa). It counts almost 70 Member States. The ICGEB is a not for profit IGO any revenues generated are re-invested in research and in the funding programs for capacity building in its Member States. The Vision of the ICGEB is to be the world's leading intergovernmental Organization for research, training, and technology transfer in the field of Life Sciences and Biotechnology. Its Mission is to combine scientific research with capacity enhancement, thereby promoting sustainable global development (https://www.icgeb.org/). The Molecular Virology Group in Trieste studies the detection and molecular mechanisms of different arboviruses and has been mainly involved in the response to the COVID-19 pandemic providing support to the ICGEB Member countries. Activities included in the formulation for protocols for SARS-CoV-2 molecular and serological diagnostics, online tutorials and reagents to be able to develop low-cost in-house assays. COVID-19 viruses circulating in several countries have been sequenced for the first time and made available to the scientific community. A pipeline for testing antivirals against SARS-CoV-2 has been set-up allowing the identification of novel drug candidates. TSX-V: SBM www.sironabiochem.com About Sirona Biochem Corp. Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential. Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona's laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com. For more information regarding this press release, please contact: Investor Enquiries: Email: Info@sironabiochem.com Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. --------------------------------------------- Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward- looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.